Villa Igea Hospital, Department of Ophthalmology, Forlì, Italy; Centre For Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Villa Igea Hospital, Department of Ophthalmology, Forlì, Italy; Alexandria University, Department of Ophthalmology, Alexandria, Egypt.
Am J Ophthalmol. 2013 Sep;156(3):608-615.e1. doi: 10.1016/j.ajo.2013.04.022. Epub 2013 Jun 7.
To report the results of Descemet stripping automated endothelial keratoplasty (DSAEK) to treat endothelial failure in eyes with buphthalmos.
Prospective interventional case series.
All buphthalmic eyes with endothelial failure undergoing DSAEK by the same surgeon (M.B.) between March 2007 and January 2012 were included. Outcome measures included best spectacle-corrected visual acuity (BSCVA), refraction, and endothelial cell loss (assessed 6, 12, 24, 36, and 48 months postoperatively). Standardized DSAEK was performed in all cases, with minor modifications in phakic and aphakic eyes. Other outcomes included comparisons to penetrating keratoplasty (PK) published results and comparisons to visual outcomes in DSAEK for other indications.
There were 14 transplants performed in 12 eyes (11 patients). Mean age was 34.9 years (range 15-54 years). The average follow-up was 21.7 ± 13.8 months (range 6-48 months). At last follow-up examination, BSCVA had improved in 11 of 13 cases, with a logMAR average value ± standard deviation of 0.74 ± 0.66 from the preoperative value of 2.07 ± 0.80. Eleven eyes reached Snellen acuity of 20/200 or better, and 5 eyes reached 20/40 or better. Mean endothelial cell loss was 40.5% ± 8.9% (range 23.7%-53.1%). Complications included graft detachment (n = 2), glaucoma progression (n = 1), and late endothelial failure (n = 1). All complications were managed successfully either by repeat DSAEK (n = 2), rebubbling (n = 1), or cyclocryocoagulation (n = 1).
DSAEK may be performed safely and effectively in buphthalmic eyes, with comparable results to outcomes after PK. Visual outcomes are not substantially different after DSAEK for this indication compared to DSAEK for other indications.
报告经表皮角膜内皮移植术(DSAEK)治疗先天性青光眼伴大泡性角膜病变的内皮功能失代偿的结果。
前瞻性干预性病例系列研究。
所有由同一位医生(M.B.)施行的大泡性角膜病变伴内皮功能失代偿的先天性青光眼患者均被纳入该研究。主要的观察指标包括最佳矫正视力(BSCVA)、屈光度和内皮细胞丢失(术后 6、12、24、36 和 48 个月进行评估)。所有患者均行标准 DSAEK 手术,对有晶状体眼和无晶状体眼进行了微小的修改。其他结果包括与穿透性角膜移植术(PK)的研究结果进行比较,以及与其他适应证的 DSAEK 手术的视力结果进行比较。
12 只眼中共施行 14 例 DSAEK 手术(11 例患者)。平均年龄为 34.9 岁(15-54 岁)。平均随访时间为 21.7±13.8 个月(6-48 个月)。末次随访时,13 例中有 11 例视力提高,术后平均最佳矫正视力(logMAR 视力)为 0.74±0.66,优于术前的 2.07±0.80。11 只眼达到 20/200 或更好的 Snellen 视力,5 只眼达到 20/40 或更好。平均内皮细胞丢失率为 40.5%±8.9%(23.7%-53.1%)。并发症包括:移植物脱离(n=2)、青光眼进展(n=1)和晚期内皮功能失代偿(n=1)。所有并发症均通过再次施行 DSAEK(n=2)、再注气(n=1)或睫状体冷冻术(n=1)成功处理。
DSAEK 可安全有效地应用于先天性青光眼伴大泡性角膜病变的患者,其结果与 PK 相似。与其他适应证的 DSAEK 相比,该适应证的 DSAEK 术后视力结果并无显著差异。